AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04004403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
Study NCT01180517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: balloon angioplasty
Study NCT01180517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: balloon angioplasty
Study NCT00906958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexus Flow Generator
Description: The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
Study NCT00906958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAP Flow Generator 25
Description: Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
Study NCT01150201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: For CKD treatment
Study NCT01150201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Control
Study NCT01860898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Description: Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
Study NCT04542720 — intervention group
Intervention type: PROCEDURE
Intervention: Observational: Decompression
Description: Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
Study NCT04542720 — intervention group
Intervention type: PROCEDURE
Intervention: Observational: Extension Fusion
Description: Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
Study NCT02365415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 8 weeks oral sirolimus, following drug levels
Study NCT03322423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 1
Description: Dailies Total 1 Multifocal Contact Lens
Study NCT03322423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 2
Description: Biotrue ONEday for Presbyopia Contact Lenses
Study NCT03322423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spherical Contact Lens 2
Description: BioTrue ONEDay Spherical
Study NCT01167868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FosD
Description: oral tablet
Study NCT01167868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT00535821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring - CardioQ, Deltex Inc
Description: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
Study NCT00535821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central line with CVP and continuous ScvO2 monitoring
Description: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
Study NCT06276790 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound-guided/hysteroscopic curettage
Description: ultrasound-guided/hysteroscopic curettage
Study NCT06276790 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure/Surgery: laparoscopic removal of the pregnancy lesion
Description: laparoscopic removal of the pregnancy lesion
Study NCT03328923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg brown seaweed powder
Study NCT03328923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02337166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate
Description: 0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
Study NCT02337166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal flap surgery
Study NCT01640665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
Study NCT01640665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
Study NCT04652674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine visit
Description: A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
Study NCT04652674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person postoperative visit
Description: A standard-of-care in-person postoperatively visit with the patient's surgeon
Study NCT02528357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
Study NCT02528357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
Study NCT01864161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gluconate iron
Description: FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
Study NCT01864161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal iron
Description: Sideral forte 30 mg/die
Study NCT04102722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUST device
Description: Imaging with MUST device
Study NCT01423474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy
Description: 40 Gy / 5 fractions / 11 days
Study NCT01423474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy
Description: 40 Gy / 5 fractions / 29 days
Study NCT02132273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Story
Description: Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
Study NCT02413411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA/MI Intervention
Description: Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
Study NCT02413411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an educational program (an NIH-developed booklet)
Study NCT00631527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Once a day by mouth for 2 weeks.
Study NCT00631527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Radiation treatment once daily over a period of 8 weeks.
Study NCT01198054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease
Study NCT00499902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: alfimeprase
Description: Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
Study NCT01760811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erbitux,merck serono
Description: cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
Study NCT02017561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
Study NCT02017561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
Study NCT02017561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
Study NCT02965690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Biomet NexGen CR
Description: Total Knee Replacement
Study NCT02965690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medacta International GMK Sphere
Description: Total Knee Replacement
Study NCT02564328 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous stem cell transplantation
Description: Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
Study NCT01914406 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high intense interval training
Description: Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
Study NCT01914406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous moderate training
Description: Continued exercise 45 min.
Study NCT01894165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1101
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Study NCT01894165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Study NCT01163708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophecy Technique
Description: Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
Study NCT01163708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation System
Study NCT01236937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bellows-based breath hold device
Description: Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed.
Study NCT01236937 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Bellows-based breath hold device
Description: Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed.
Study NCT02115711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker
Description: The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
Study NCT04157608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Prosthesis
Description: Habitual baseline prosthesis prescribed by participant's clinician.
Study NCT04157608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-Harvesting Mesofluidic Impulse Prosthesis
Description: e-MIP is an experimental lower limb ankle-foot prosthesis.
Study NCT03311659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
Study NCT03504696 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT01998698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Phacoemulsification surgery with intraocular lens implantation and monovision correction
Study NCT01998698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Phacoemulsification surgery with multifocal intraocular lens implantation
Study NCT03747432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Procedural sedation during TAVR procedure using propofol
Study NCT03747432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Procedural sedation during TAVR procedure using dexmedetomidine
Study NCT04287712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma lipids
Description: Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
Study NCT02229136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miracle Mouthwash Plus Hydrocortisone
Description: Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
Study NCT02229136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone oral solution 15 mg/5 ml
Study NCT02051777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement 1
Description: Containing macro and micronutrients
Study NCT02703688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Homes
Description: The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
Study NCT02703688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
Study NCT00513955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00513955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00513955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00513955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00513955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00513955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00513955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT03829956 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoral tongue stimulator (Snoozeal)
Description: Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
Study NCT00810940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbelaDrug200
Description: IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
Study NCT00810940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: mannitol plus standard treatment
Study NCT02051777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement 2
Description: Containing macro and micronutrients
Study NCT02051777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Advice
Study NCT03792152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
Study NCT03792152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
Study NCT04073160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
Study NCT04073160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle.
Study NCT04073160 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bladder radiation
Description: During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
Study NCT04073160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesicular Therapy
Description: Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.